Información del artículo
Resumen
En la esclerosis sistémica, el esófago se afecta en un 90%, seguido de los tramos anorrectal (50-70%), gástrico (40- 70%), colon (10-50%) e intestino delgado (40%). Las manifestaciones esofágicas son la disfagia, el reflujo gastroesofágico y sus complicaciones. Las alteraciones gástricas son consecuencia de la gastroparesia (náuseas, plenitud posprandial, entre otras). La afección intestinal produce hipomotilidad (distensión abdominal, absorción intestinal deficiente, sobrecrecimiento bacteriano, seudoobstrucción intestinal). A nivel de colon hay divertículos, constipación intestinal e incontinencia fecal. Para el diagnóstico son útiles los estudios con medio de contraste, la endoscopia del tubo digestivo superior, vaciamiento gástrico, pH-metría, manometría esofágica y rectal, así como estudios para investigar el síndrome de absorción intestinal deficiente. Los procinéticos son fundamentales en el tratamiento de las manifestaciones de hipomotilidad del tubo digestivo, aunados con los inhibidores de la bomba de protones en casos de trastornos esofágicos y los antibióticos si hay sobrecrecimiento bacteriano.
Palabras clave:
Esclerosis sistémica
Tracto gastrointestinal
Manifestaciones clínicas
Diagnóstico
Tratamiento
In systemic sclerosis esophagus is affected in 90% followed by anal and rectal involvement (50-70%), stomach (40-70%), colon (10-50%) and small bowel (40%). The main clinical findings are esophagic: dysphagia and sign of gastroesophageal reflux and its complications. Gastric symptomatology is a consequence of gastroparesis (postprandial fullness, nausea). Intestinal affection produces hypomotility (abdominal distention, deficient intestinal absorption, bacterial overgrowth). In colon there are diverticula, intestinal constipation, and fecal incontinence. For the diagnosis of GIT involvement the following are useful: studies of digestive tract with contrast media, endoscopy of upper GIT; gastric emptying; pH metry; esophageal and rectal manometry, as well as test to investigate deficient intestinal absorption syndrome. The prokinetic are a cornerstone for the treatment of hypomotility of GIT, along with pump proton inhibitors for the esophageal alteration and antibiotics for bacterial overgrowth.
Key words:
Systemic sclerosis
Gastrointestinal tract
Clinical manifestation
Diagnosis
Treatment
El Texto completo está disponible en PDF
Bibliografía
[1.]
O. Vera Lastra.
Esclerosis sistémica.
Med Int Mex, 22 (2006), pp. 231-245
[2.]
S. Rose, M.A. Young, J.C. Reynolds.
Gastrointestinal manifestations of scleroderma.
Gastroenterol Clin North Am, 27 (1998), pp. 563-594
[3.]
M.A. Young, S. Rose, J.C. Reynolds.
Gastrointestinal manifestations of scleroderma.
Rheum Dis Clin North Am, 22 (1996), pp. 797-823
[4.]
H. Sallam, T.A. McNearney, J.D. Chen.
Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).
Aliment Pharmacol Ther, 15 (2006), pp. 691-712
[5.]
G. Bassotti, E. Battaglia, V. Debernardi, U. Germani, F. Quiriconi, L. Dughera, et al.
Esophageal dysfunction in scleroderma.
Arthritis Rheum, 40 (1997), pp. 2252-2259
[6.]
M. Abu-Shakra, F. Guillemin, P. Lee.
Gastrointestinal manifestation of systemic sclerosis.
Sem Arthritis Rheum, 24 (1994), pp. 29-39
[7.]
J. Hamel-Roy, G. Devroede, P. Arhan, L. Tetreault, A. Duranceau, H. Menard.
Comparative esophageal and anorectal motility in scleroderma.
Gastroenterology, 88 (1985), pp. 1-7
[8.]
P.J. Clements.
Systemic sclerosis (scleroderma) and related disorders: clinical aspect.
Baillieres Clin Rheumatol, 14 (2000), pp. 1-16
[9.]
Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-controlled study of the pathology of oesophageal disease in systemic [epub antes de imprenta] Gut. 2006; Mar 9.
[10.]
W.M. Weinstein, B.M. Kadell.
The gastrointestinal tract in systemic sclerosis.
Systemic sclerosis, 2.ª ed., pp. 293-317
[11.]
V.D. Steen, T.A. Medsger Jr.
Severe organ involvement in systemic sclerosis with diffuse scleroderma.
Arthritis Rheum, 43 (2000), pp. 2437-2444
[12.]
R.O. Dantas, L.R. Aprile.
Esophageal striated muscle contractions in patients with gastroesophageal reflux symptoms.
Dig Dis Sci, 47 (2002), pp. 2586-2590
[13.]
K. Jaovisidla, M.E. Csuka, U.A. Almargo, K.H. Soergel.
Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature.
Seminars Arthritis Rheum, 34 (2004), pp. 689-702
[14.]
A.J. Geirsson, F.A. Wollheim, A. Akesson.
Disease severity of 100 patients with systemic sclerosis over period of 14 years: using a modified Medsger scale.
Ann Rheum Dis, 60 (2001), pp. 1117-1122
[15.]
J. Wipff, Y. Allanore, F. Soussi, B. Terris, V. Abitbol, J. Raymond, et al.
Prevalence of Barrett’s esophagus in systemic sclerosis.
Arthritis Rheum, 59 (2005), pp. 2882-2888
[16.]
Y. Niv, S. Abu-Avid, A. Yelin, Y. Liberman.
Barrett’s ephithelium and esophageal adenocarcinoma in scleroderma.
Am J Gastroeneterol, 83 (1988), pp. 792-793
[17.]
E.I. Heath, P.J. Limburg, E.T. Hawk, et al.
Adenocarcinoma of the esophagus: risk factors and prevention.
Oncology (Huntingt), 14 (2000), pp. 507-514
[18.]
M.A. Contreras, C. Salas, J.L. Andreu, J. Mulero.
Cytomegalovirus esophagitis as a treatable complication of systemic sclerosis.
J Clin Rheumatol, 7 (2001), pp. 384-387
[19.]
I. Marie, S. Dominique, H. Levesque, P. Durcrotte, P. Denis, M.F. Hellot, et al.
Esophageal involvement and pulmonary manifestations in systemic sclerosis.
Arthritis Rheum, 45 (2001), pp. 346-354
[20.]
A.J. Ing.
Interstitial lung disease and gastroesophageal reflux.
Am J Med, 111 (2001), pp. S41-S44
[21.]
S.M. Al-Amri.
The pattern of esophageal manometry in progressive systemic sclerosis.
Saudi Med J, 24 (2003), pp. 68-71
[22.]
A. Bestetti, F. Carola, L. Conciato, B. Marasini, G.L. Torolo.
Esophageal scintigraphy with a semisolid meal to evaluate esophageal dysmotility is systemic sclerosis and Raynaud’s phenomenon.
J Nucl Med, 40 (1999), pp. 77-84
[23.]
P.L. Peghini, P.O. Katz, D.O. Castell.
Ranitidine controls nocturnal gastric acid breakthrough on omeprazol: a controlled study in normal subjects.
Gastroenterology, 115 (1998), pp. 1335-1339
[24.]
D. Gillen, A.A. Wirz, J.E. Ardill.
Rebound hypersecretion alter omeprazol and its relation to on-treatment acid suppression and Helicobacter pylori status.
Gastroenterology, 116 (1999), pp. 239-247
[25.]
U. Mercado, R. Arroyo de Anda, L. Avendano, R. Araiza-Casillas, M. Avendano-Reyes.
Metoclopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities.
Clin Exp Rheumatol, 23 (2005), pp. 685-688
[26.]
O. Vera Lastra, L.E. Rodríguez Molinar, A. Normandia Almeida, A. Rodríguez Alejandre, C.E. Lira Carreon, L.J. Jara, et al.
Utilidad de la eritromicina en la gastroparesia por esclerodermia. Estudio comparativo con metoclopramida.
Rev Mex Reumat, 16 (2001), pp. 361-366
[27.]
R. Linke, M. Meier, W. Muenzing, C. Folwaczny, O. Schnell, K. Tatsch.
Prokinetic therapy: what can be measured by gastric scintigraphy?.
Nucl Med Commun, 26 (2005), pp. 527-533
[28.]
I. Marie, H. Levesque, P. Ducrotté, P. Denis, M.F. Hellot, J. Benichou, et al.
Gastric involvement in systemic sclerosis: a prospective study.
Am J Gastroeneterol, 96 (2001), pp. 77-83
[29.]
K.R. Sridhar, R.C. Lange, L. Magyar, I. Soykan, R.W. McCallun.
Prevalence of impaired gastric of solid in systemic sclerosis: diagnosis and therapeutic implications.
J Lab Clin Med, 132 (1998), pp. 541-546
[30.]
H.D. Allescher, A. Bockenhoff, G. Knapp, M. Wienbeck, J. Hartung.
Treatment of non ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies.
Scan J Gastroenterol, 36 (2001), pp. 934-941
[31.]
M. Horowitz, G.J. Maddern, A. Maddox, J. Wishart, B.E. Chatterton, D.J.C. Shearman.
Effect of cisapride on gastric and esophageal empting in progressive systemic sclerosis.
Gastroeneterology, 93 (1987), pp. 311-315
[32.]
S.J. Wang, S.J. La, D.Y. Chen, Y.H. Chen, T.Y. Hsieh, W.Y. Lin.
Effects cisapride on oesophageal transit of solid in patients with progressive systemic sclerosis.
Clin Rheumatol, 21 (2002), pp. 43-45
[33.]
C. Enger, C. Cali, A.M. Walker.
Serious ventricular arrhythmias among user of cisapride and other QT-prolonging agent in the United States.
Pharmacoepidemiol Drug Saf, 11 (2002), pp. 477-486
[34.]
J. Dull, J.P. Rautman, D. Zakai, A. Strashun, E.W. Straus.
Successful treatment of gastroparesis with erythromycin in a patient with progressive systemic sclerosis.
Am J Med, 89 (1990), pp. 528-529
[35.]
V. Annese, J. Janssen, G. Vantrappen, J. Tack, T.L. Peeters, P. Willeinse, et al.
Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination.
Gastroenetrology, 102 (1992), pp. 823-828
[36.]
S. Fiorucci, E. Distrutti, R. Gerli, A. Morelli.
Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term.
Am J Gastrenterol, 89 (1994), pp. 550-555
[37.]
L.S. Miller, G.A. Szych, S.B. Kantor, M.Q. Bromer, L.C. Knight, A.H. Maurer, et al.
Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle.
Am J Gastroenterol, 97 (2002), pp. 1653-1660
[38.]
M. Watson, R.J. Hally, P.A. McCue, J. Varga, S.A. Jimenez.
Gastric antral estasia (watermelon stomach) in patients with systemic sclerosis.
Arthritis Rheum, 39 (1996), pp. 341-346
[39.]
O. Elkayam, M. Oumanski, M. Yaron, D. Caspi.
Watermelon stomach following and preceding systemic sclerosis.
Seminars Arthritis Rheum, 30 (2000), pp. 127-131
[40.]
K.F. Binmoeller, R.M. Katon.
Bipolar electrocoagulation for watermelon stomach.
Gastrointest Endosc, 36 (1990), pp. 399-402
[41.]
J.D.R. Rose.
Endoscopic injection of alcohol for bleeding from gastroduodenal vascular anomalies.
Br Med J, 295 (1987), pp. 93-94
[42.]
O. Vera Lastra, J. Mayoral, P. Baltazar Montufar, P. Ramírez Mendoza, R. Ariza Andraca.
Alteraciones gastroesofágicas y factores de riesgo condicionantes en pacientes con esclerodermia.
Med Int Mex, 12 (1996), pp. 3
[43.]
A. Attar.
Digestive manifestations in systemic sclerosis.
Ann Med Interne (Paris), 153 (2002), pp. 260-264
[44.]
R.M. Boerner, D.B. Fried, D.M. Warshauer, K. Isaacs.
Pneumatosis intestinalis: two cases reports and a retrospective review of the literature from 1985 to 1995.
Dig Dis Sci, 41 (1996), pp. 2272-2285
[45.]
P.P. Toskes.
The changing nature of small intestine bacterial overgrowth.
Curr Gastroenetrol Rep, 1 (1999), pp. 267-268
[46.]
I. Hirano, J. Pandolfino.
Chronic intestinal pseudo-obstruction.
Dig Dis, 18 (2000), pp. 83-92
[47.]
S.D. Mann, H.S. Debinsky, M.A. Kamm.
Clinical characteristic of chronic idiopathic intestinal pseudo-obstruction in adults.
Gut, 41 (1997), pp. 675-681
[48.]
P.P. Toskes.
The changing nature of small intestinal bacterial overgrowth.
Curr Gastroenterol Rep, 1 (1999), pp. 267-268
[49.]
F. Shanahan, J. McCarthy.
Functional foods and probiotic: time for gastroenterologist to embrace the concept.
Curr Gastroenterol Rep, 2 (2000), pp. 345-346
[50.]
A. Attar, B. Fluorie, J.C. Rambaud, C. Franchisseur, P. Ruszniewski, Y. Bouhnik.
Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.
Gastroenterology, 117 (1999), pp. 794-797
[51.]
G.E. Boeckxstaens, J.F.W.M. Bertelsman, L. Lauwers, G.N.J. Tytgat.
Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride.
Am J Gatroenterol, 97 (2002), pp. 197-207
[52.]
H.C. Soudan, W.L. Hasler, C. Owyang.
Effect of octeotride on intestinal motility and bacterial overgrowth in scleroderma.
N Engl J Med, 325 (1991), pp. 1461-1467
[53.]
G.N. Verne, E.Y. Eaker, E. Hardy, C.A. Sninsky.
Effect of octeotride and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction.
Dig Dis Sci, 40 (1995), pp. 1892-1901
[54.]
T. Lecomte, M. Cavicchi, J.C. Delchier.
Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin.
Gastroenterol Clin Biol, 24 (2000), pp. 361-363
[55.]
S. Appel-Dingemanse.
Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
Clin Pharmacokinet, 41 (2002), pp. 1021-1042
[56.]
M. Corsetti, J. Tack.
Tegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome.
Exp Opin Pharmacother, 3 (2002), pp. 1211-1218
[57.]
A. Wald.
Slow transit constipation.
Curr Treat Options Gastroenetrol, 5 (2002), pp. 279-283
[58.]
U. Haque, J. Yardley, M. Talamini, F. Wigley.
Colon stricture and volvulus in a patient with scleroderma.
J Rheumatol, 26 (1999), pp. 2268-2272
[59.]
J. Hamel-Roy, G. Devroede, P. Arhan, L. Tetreault, A. Duranceau, H.A. Menard.
Comparative esophageal and anorrectal motility in scleroderma.
Gastroenterology, 88 (1985), pp. 1-8
[60.]
J.A. Leighton, M.A. Valdovinos, J.H. Pemberton, D.M. Rath, M. Camilleri.
Anorrectal dysfunction and rectal prolapse in progressive systemic sclerosis.
Dis Colon Rectum, 36 (1993), pp. 182-185
[61.]
S.J. Wang, J.L. Lan, D.Y. Chen, Y.H. Chen, T.Y. Hsieh, W.Y. Lin.
Colonic transit disorders in systemic sclerosis.
Clin Rheumatol, 20 (2001), pp. 251-254
[62.]
A.E. Bharucha, S.F. Phillips.
Slow transit constipation.
Gastroenterol Clin North Am, 30 (2001), pp. 77-97
[63.]
S.J. Wang, J.L. Lan, J.L. Lan, D.Y. Chen, Y.H. Chen, T.Y. Hsieh, et al.
Effects of cisapride on colonic transit in patients with progressive systemic sclerosis.
Clin Rheumatol, 21 (2002), pp. 271-274
[64.]
C. Norton, M.A. Kamm.
Anal sphincter biofeedback and pelvic floor exercise for faecal incontinence in adults: a systematic review.
Aliment Pharmacol Ther, 15 (2000), pp. 1147-1195
[65.]
S. Heymen, K.R. Jones, Y. Ringel, Y. Scarlett, W.E. Whitehead.
Biofeedback treatment of fecal incontinente: a critical review.
Dis Colon Rectum, 44 (2001), pp. 728-736
[66.]
A.D. Burt.
Primary cirrhosis and other ductopenic disease.
Clin Liver Dis, 6 (2002), pp. 363-380
[67.]
B. Marasini, M. Gagetta, V. Rossi, P. Ferrari.
Rheumatic disorder and primary biliar cirrhosis: an appraisal of 170 italian patients.
Ann Rheum Dis, 60 (2001), pp. 1046-1049
[68.]
W.I. Yaussef, A.S. Tavil.
Connective tissue disease and liver.
J Clin Gastroenterol, 35 (2002), pp. 345-349
[69.]
N.J. Walker, R.B. Zurier.
Liver abnormalities in rheumatic disease.
Clin Liver Dis, 6 (2002), pp. 933-946
[70.]
C. Rigamonti, L.M. Shand, M. Feudjo, C.C. Bunn, C.M. Black, C.P. Denton, et al.
Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis.
Gut, 55 (2006), pp. 388-394
[71.]
S. Akimoto, O. Ishikawa, Y. Muro, H. Takagi, T. Tamura, Y. Miyachi.
Clinical and immunological characterization of patients with systemic sclerosis overlapping primary biliar cirrhosis: a comparison with patients with systemic sclerosis alone.
J Dermatol, 26 (1999), pp. 18-22
[72.]
V. Stadie, J. Wohlrab, W.C. Marsch.
Reynolds syndrome –a rare combination of 2 autoimmune diseases.
Med Klin (Munich), 97 (2002), pp. 40-43
[73.]
I.R. Mackay.
Autoimmunity and primary biliar cirrhosis.
Baillieres Best Pract Res Clin Gastroenterol, 14 (2000), pp. 519-533
[74.]
M.M. Kaplan.
Medical progress: primary biliar cirrhosis.
N Eng J Med, 335 (1996), pp. 1570-1580
[75.]
A. Pares, L. Caballeria, J. Rodes.
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid.
Gastroenterology, 130 (2006), pp. 715-720
Copyright © 2006. Elsevier España S.L. Barcelona
